Table 1 Descriptive characteristics of patients treated with intravenous vs. intraperitoneal chemotherapy for stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease between 1995 and 2012 (n = 1263)

Characteristics

(71.4 %)

(28.6 %)

(50 %)

(50 %)

Age (y, mean)

54.3

52.6

0.017

52.7

52.6

0.002

Stage (%)

 III

671 (90.1 %)

267 (89.6 %)

0.014

254 (92.7 %)

252 (92.0 %)

0.013

 IV

74 (9.9 %)

31 (10.4 %)

−0.020

20 (7.3 %)

22 (8.0 %)

−0.021

Grade (%)

 1

119 (16.0 %)

43 (14.4 %)

0.011

33 (12.0 %)

37 (13.5 %)

−0.021

 2

429 (57.6 %)

180 (60.4 %)

−0.008

178 (65.0 %)

176 (64.2 %)

0.017

 3

197 (26.4 %)

75 (25.2 %)

0.009

63 (23.0 %)

61 (22.2 %)

0.011

Histologic subtype (%)

 Serous

371 (49.8 %)

145 (48.7 %)

0.016

142 (51.8 %)

140 (51.1 %)

0.006

 Mucinous

75 (10.1 %)

26 (8.7 %)

0.014

21 (7.7 %)

24 (8.8 %)

−0.016

 Clear cell

109 (14.6 %)

41 (13.8 %)

0.007

41 (15.0 %)

38 (13.9 %)

0.014

 Endometrioid

83 (11.1 %)

45 (15.1 %)

−0.037

48 (17.5 %)

45 (16.4 %)

0.010

 Mixed or others^a

107 (14.4 %)

41 (13.8 %)

0.009

22 (8.0 %)

27 (9.9 %)

−0.019

Front-line regimen (%)

 Paclitaxel based

661 (88.8 %)

259 (81.2 %)

0.074

245 (89.4 %)

248 (90.5 %)

−0.008

 Not paclitaxel based

84 (11.3 %)

39 (13.1 %)

−0.017

29 (10.6 %)

26 (9.5 %)

0.009

Consolidation chemotherapy (%)

 No

622 (83.5 %)

242 (83.9 %)

−0.007

202 (73.7 %)

203 (74.1 %)

−0.005

 Yes

123 (16.5 %)

56 (16.1 %)

0.008

72 (26.3 %)

71 (25.9 %)

0.006

GOG performance status

  ≤ 1

649 (87.1 %)

250 (83.9 %)

0.026

241 (88.0 %)

239 (87.2 %)

0.003

  ≥ 2

96 (12.9 %)

48 (16.1 %)

−0.027

33 (12.0 %)

35 (12.8 %)

−0.006

Charlson comorbidity index (%)

 0

637 (85.5 %)

231 (77.5 %)

0.103

223 (81.4 %)

219 (80.0 %)

0.008

  ≥ 1

108 (14.5 %)

67 (22.5 %)

−0.146

51 (18.6 %)

55 (20.0 %)

−0.014